Brought to you by 
IntelGenx scores exclusive rights to Lilly's tadalafil dosing patent
30 Mar 2017
Executive Summary
Eli Lilly & Co. granted IntelGenx Corp. exclusive rights to its US dosing patent number 6,943,166, which IntelGenx will apply to support development and marketing of its tadalafil film candidate for erectile dysfunction.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IntelGenx scores exclusive rights to Lilly's tadalafil dosing patent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice